Ensign Peak Advisors
CLDX icon

Ensign Peak Advisors’s Celldex Therapeutics CLDX Stock Holding History

Ensign Peak Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Buy
6,578
+300
+5% +$9.69K ﹤0.01% 1269
2026
Q1 		$199K Hold
6,278
– – ﹤0.01% 1313
2025
Q4 		$171K Sell
6,278
-9,600
-60% -$253K ﹤0.01% 1378
2025
Q3 		$411K Sell
15,878
-8,200
-34% -$190K ﹤0.01% 1474
2025
Q2 		$490K Hold
24,078
– – ﹤0.01% 1558
2025
Q1 		$437K Buy
24,078
+650
+3% +$14.5K ﹤0.01% 1581
2024
Q4 		$592K Hold
23,428
– – ﹤0.01% 1553
2024
Q3 		$796K Hold
23,428
– – ﹤0.01% 1444
2024
Q2 		$867K Sell
23,428
-155,001
-87% -$5.85M ﹤0.01% 1373
2024
Q1 		$7.49M Sell
178,429
-1,182
-0.7% -$48.5K 0.01% 524
2023
Q4 		$7.12M Buy
179,611
+87,482
+95% +$2.57M 0.01% 534
2023
Q3 		$2.54M Hold
92,129
– – 0.01% 760
2023
Q2 		$3.13M Hold
92,129
– – 0.01% 726
2023
Q1 		$3.31M Hold
92,129
– – 0.01% 678
2022
Q4 		$4.11M Buy
92,129
+81,419
+760% +$2.91M 0.01% 607
2022
Q3 		$301K Hold
10,710
– – ﹤0.01% 1706
2022
Q2 		$289K Hold
10,710
– – ﹤0.01% 1694
2022
Q1 		$365K Hold
10,710
– – ﹤0.01% 1682
2021
Q4 		$414K Buy
+10,710
New +$467K ﹤0.01% 1691

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ensign Peak Advisors's CLDX Position: Q2 2026 in Review

Ensign Peak Advisors increased its Celldex Therapeutics (CLDX) stake by 4.8% in Q2 2026, buying an estimated $9.69K and bringing the position to 6,578 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #1269.

Ensign Peak Advisors first reported a position in CLDX in Q4 2021 and has held it in 19 quarters since. The position peaked at $7.49M in Q1 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Ensign Peak Advisors held 6,578 shares of Celldex Therapeutics worth $245K as of Q2 2026.
  • Ensign Peak Advisors bought 300 Celldex Therapeutics shares in Q2 2026, an estimated $9.69K.
  • Celldex Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1269 holding.
  • Ensign Peak Advisors first reported a position in Celldex Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Ensign Peak Advisors's Celldex Therapeutics position peaked at $7.49M in Q1 2024.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.